Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL234737 | 0.86 | TSHR (0.43) | TSHRALDH1A1TDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL31058602 | 0.84 | TSHR (0.42) | TSHRALDH1A1TDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL5972501 | 0.83 | TSHR (0.41) | TSHRALDH1A1TDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7155936 | 0.83 | TSHR (0.41) | TSHRALDH1A1TDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL5972658 | 0.81 | TSHR (0.39) | TSHRALDH1A1TDP1L3MBTL1MMP8 | |
| SCHEMBL5972522 | 0.81 | TSHR (0.39) | TSHRALDH1A1TDP1L3MBTL1MMP8 | |
| SCHEMBL6892165 | 0.81 | TSHR (0.39) | TSHRALDH1A1TDP1L3MBTL1MMP8 | |
| SCHEMBL560964 | 0.81 | TSHR (0.39) | TSHRALDH1A1TDP1L3MBTL1MMP8 | |
| SCHEMBL25899867 | 0.81 | EGFR (0.35) | ALDH1A1MMP8MAPTLMNA | |
| SCHEMBL29343775 | 0.80 | LMNA (0.32) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-20230144534-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| CN-109952360-B | Quantum dot dispersion, self-luminous photosensitive resin composition, color filter manufactured using the same, and image display device | 东友精细化工有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-10428058-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-10-01 | — | — | US | disclosed |
| US-20190284181-A9 | PRODRUGS OF NH-ACIDIC COMPOUNDS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-09-19 | — | — | US | disclosed |
| US-20190031648-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES PHARMA IRELAND LTD (IE) | 2019-01-31 | — | — | US | disclosed |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-08-07 | — | — | US | disclosed |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-08-07 | — | — | US | disclosed |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-17 | — | — | US | disclosed |
| US-10011569-B2 | Process for synthesizing oxidized lactam compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-03 | — | — | US | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011569-B2 | Process for synthesizing oxidized lactam compounds | COASY, DHPS, OXA1L | TSHR 4488/4885ALDH1A1 113/4885TDP1 4453/4885 |
| US-20190031648-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | TSHR 3738/4885ALDH1A1 1082/4885TDP1 3433/4885 |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | TSHR 1280/4885ALDH1A1 599/4885TDP1 2311/4885 |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | TSHR 3738/4885ALDH1A1 1082/4885TDP1 3433/4885 |
| US-20190284181-A9 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | TSHR 3738/4885ALDH1A1 1082/4885TDP1 3433/4885 |
| US-20110166194-A1 | Asenapine Prodrugs | GRIN1, SCN1B, GRIN2B | TSHR 520/4885ALDH1A1 432/4885TDP1 718/4885 |
| US-20230144534-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | KIT, TPSB2, BTD | TSHR 617/4885ALDH1A1 760/4885TDP1 1334/4885 |
| US-10428058-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | TSHR 3738/4885ALDH1A1 1082/4885TDP1 3433/4885 |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | SLC1A2, BDNF, MAOB | TSHR 1502/4885ALDH1A1 307/4885TDP1 1148/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | TSHR 1280/4885ALDH1A1 599/4885TDP1 2311/4885 |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | HTR5A, HTR2C, HTR2B | TSHR 3059/4885ALDH1A1 760/4885TDP1 388/4885 |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | TSHR 3738/4885ALDH1A1 1082/4885TDP1 3433/4885 |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | TSHR 1280/4885ALDH1A1 599/4885TDP1 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.